Research, Development and Commercialization Agreement Sample Contracts

AMENDMENT NO. 2 to RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT, DATED MAY 24, 2004, by and between VERTEX PHARMACEUTICALS INCORPORATED and CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INCORPORATED
Research, Development and Commercialization Agreement • October 13th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations

This Amendment No. 2 (the “Second Amendment”) is made as of January 1, 2006 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with its principal offices at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 (“Vertex”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”).

Sample 1Sample 2
AutoNDA by SimpleDocs
AMENDMENT NO. 2 to RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT, DATED MAY 24, 2004, by and between VERTEX PHARMACEUTICALS INCORPORATED and CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INCORPORATED
Research, Development and Commercialization Agreement • August 19th, 2011 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations

This Amendment No. 2 (the “Second Amendment”) is made as of January 1, 2006 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with its principal offices at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 (“Vertex”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”).

Sample 1
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN ICAGEN, INC. AND CYSTIC FIBROSIS FOUNDATION RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT CONTENTS
Research, Development and Commercialization Agreement • April 28th, 2022 • OmniAb, Inc. • Services-commercial physical & biological research • Delaware

This Agreement (this “Agreement”) is made on this 1st day of May, 2018 and shall be effective on the Effective Date by and between Icagen, Inc. (“Icagen”), a corporation having a principal place of business at [***] acting on behalf of itself and Affiliates, and Cystic Fibrosis Foundation (“CFF”), a nonprofit corporation with its principal offices at [***], and shall become effective on the Effective Date. Icagen and CFF are each referred to herein individually as a “Party” and collectively as the “Parties”.

Sample 1
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between Sangamo BioSciences, Inc. and Juvenile Diabetes Research Foundation International
Research, Development and Commercialization Agreement • March 1st, 2007 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances) • Delaware

This Agreement (this “Agreement”) is made on this 24th day of October, 2006, by and between Sangamo BioSciences, Inc., a Delaware corporation, with its principal office at 501 Canal Boulevard, Suite A100, Richmond, CA 94804 (“Sangamo”) and Juvenile Diabetes Research Foundation International, a Pennsylvania nonprofit corporation with its principal offices at 120 Wall Street, New York, NY 10005 (“JDRF”). This Agreement shall become effective on the Effective Date (as defined below). Sangamo and JDRF are each a “Party,” and, collectively, the “Parties.”

Sample 1
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
Research, Development and Commercialization Agreement • May 10th, 2006 • Entremed Inc • Biological products, (no disgnostic substances)

This Research, Development and Commercialization Agreement (“Agreement”) is entered into as of this 20th day of April, 2005, by and between:

Sample 1
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
Research, Development and Commercialization Agreement • December 23rd, 2008 • Via Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware

This Research, Development and Commercialization Agreement (“Agreement”) is signed as of this 18th day of December, 2008, by and between:

Sample 1
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between Proteostasis Therapeutics, Inc. and Cystic Fibrosis Foundation Therapeutics, Inc. Dated March 20, 2012
Research, Development and Commercialization Agreement • December 23rd, 2015 • Proteostasis Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts

This Agreement is made on this 20th day of March, 2012 (the “Effective Date”) by and between Proteostasis Therapeutics, Inc. (“PTI”), a Delaware corporation with its principal office at 200 Technology Square, Fourth Floor, Cambridge, MA 02139, and Cystic Fibrosis Foundation Therapeutics, Inc. (“CFFT”), a nonprofit corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland, 20814, and shall become effective on the Effective Date (as defined herein). PTI and CFFT are each a “Party,” and, collectively, the “Parties.”

Sample 1
AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
Research, Development and Commercialization Agreement • March 11th, 2009 • Xoma LTD /De/ • Pharmaceutical preparations

This Amended and Restated Research, Development and Collaboration Agreement (this “Agreement”) is effective as of July 1, 2008 (the “Effective Date”) by and between Novartis Vaccines and Diagnostics, Inc. (f/k/a Chiron Corporation), a Delaware corporation with offices at 4650 Horton Street, Emeryville, California 94608 (together with its Affiliates, “NVDI”), and XOMA (US) LLC, a Delaware limited liability company with offices at 2910 Seventh Street, Berkeley, California 94710 (together with its Affiliates, “XOMA”). NVDI and XOMA are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” When used in this Agreement, capitalized terms shall have the meanings set forth in Article 1.

Sample 1
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
Research, Development and Commercialization Agreement • December 23rd, 2008 • Via Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware

This Research, Development and Commercialization Agreement (“Agreement”) is entered into as of this 18th day of December, 2008, by and between:

Sample 1
BETWEEN
Research, Development and Commercialization Agreement • November 9th, 2006 • EPIX Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Maryland
Sample 1
Time is Money Join Law Insider Premium to draft better contracts faster.